Initial combination of metformin, sitagliptin, and empagliflozin in drug‐naïve patients with type 2 diabetes: Safety and metabolic effects

Corresponding Author

Soo Lim MD

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea

Correspondence

Soo Lim, MD, PhD Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea Tel: +82-31-787-7035, Fax: +82-31-787-4051, Email: limsoo@snu.ac.kror Ele Ferrannini, MD, PhD CNR Institute of Clinical Physiology, Pisa, Italy Tel: +39-050-553272,

Email: ferranni@ifc.cnr.it

Search for more papers by this author

留言 (0)

沒有登入
gif